Browsing by Author "Sousa, A. S."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Antibacterial and antioxidant potential of aqueous extracts of bio-residues from agrocybe cylindracea and pleurotus ostreatus myceliumPublication . Sousa, A. S.; Marçal, S.; Costa, C.; Ferreira, I.; Barros, J.; Nunes, J.; Freitas, A. C.; Morais, A. M. M. B.; Pintado, M.The production of fresh mushrooms results in a large quantity of bio-residues, which may account for more than 20% of a crop volume and contributes to production costs and environmental impact, if not used. These products consist mainly of stalks, mushrooms of irregular dimensions and shape and basal material. Thus, the main objective of MicoBioExtract project is the valorisation of these bio-residues and the development of add-value by-products with bioactive compounds such as polysaccharides and phenolic compounds produced by mushrooms. In the present work, the aqueous extracts from Agrocybe cylindracea byproducts (ACB) and Pleurotus ostreatus mycelium (POM) were evaluated for potential antioxidant and antimicrobial activities. Water soluble substances were extracted from mushrooms according to two different methods. In method 1 it was performed a hot extraction (extract 1A; 90 °C; 1 h; 500 rpms). In method 2, the biomass was submitted to an extraction at room temperature (extract 2B) and the resulting residue was extracted with hot water (extract 2C; 90 °C; 1 h; 500 rpms). The aqueous extracts from POM were obtained only by method 1. Extracts were lyophilized and their bioactivity evaluated measuring the antioxidant (ABTS, DPPH and ORAC) and antimicrobial (determination of the minimum inhibitory concentration – MIC) activities. The mutagenicity was also tested (Ames assay with and without S9). Moreover, it was determined the total phenolics content of the extracts and α and β – glucans (Folin Ciocalteu and Beta-Glucan Assay methods, respectively). The results obtained from antioxidant methods showed that all extracts from both mushrooms are a potential source of natural antioxidant and phenolic compounds. According to ABTS, extract 2B from ACB showed the best value with 8.48±0.33 mg ascorbic acid equivalent (AAE)/g dry extract and 4.14±0.52 mg AAE/g dry extract for POM. Regarding the antimicrobial activity, MIC results showed that ACB and POM extracts inhibited the growth of Gram- (Salmonella enteritidis) and Gram+ (Bacillus cereus and Listeria monocytogenes). Concerning the mutagenicity, the results showed no toxic effect except for extract 1A from ACB. Regarding the β-glucan content, the extracts from ACB presented higher content of β-glucan than the C extracts from POM. Thus, aqueous extracts from mushroom bio-residues showed potential antioxidant and antimicrobial properties and to develop a circular bioeconomy approach.
- gBIOT - Nutraceutical biopolymeric-biocatalytic microbot against gut inflammatory disordersPublication . Sousa, A. S.; Pintado, M. M.; Matos, R. D.; Sousa, C. C.; Machado, M. F.; Coelho, M.; Rodrigues, P. M.; Magalhães, A. M.; Coscueta, E. R.gBiOT is a novel project that proposes micro-robotic technology for nutraceuticals and therapeutic foods for gastrointestinal tract disorders. Gastrointestinal disorders have high prevalence and morbidity, leading to neoplasia and cancer. Recent advances in nanotechnology have opened up new opportunities in the food sector, allowing for the development of health-food products containing nanosized ingredients that can benefit the entire food chain. However, colon-targeted drug delivery systems have gained the most attention as potential carriers for the local treatment of colonic disorders. While current delivery systems have some benefits, they must be improved to be more than passive delivery systems. Advanced steps would include developing biocompatible devices that can actively identify inflamed regions in the gastrointestinal tract, counteract proinflammatory metabolites, and release drugs to alleviate abnormality. Such devices could propel themselves in the gastrointestinal tract environment, making them active in various tasks. gBiOT aims to address these unmet needs by developing a modular microbot prototype that executes intelligent functions under gastrointestinal disorders. The project is developing functionalized microbots that will test to assess the microbiota interaction and preclinical tests. This would lead to the development of practical solutions for the prophylaxis and control of gastrointestinal diseases with minimal impact on patient quality of life and via sustainable methodologies.